

## Review

# Cognitive behavioural therapy for sleep problems in psychosis: systematic review of effectiveness and acceptability

Hannah Wilkinson, Louise C. Johns, Rachel Batchelor and Alex Lau-Zhu

## Background

Sleep problems are common among people with psychosis. Research suggests poor sleep is causally related to psychosis, anxiety and depression.

## Aims

This review investigates the effectiveness and acceptability of cognitive-behavioural therapy (CBT) in targeting sleep problems in people with and at risk of psychosis.

## Method

Four databases were searched in line with PRISMA guidelines. Eligible studies either evaluated (a) CBT targeting sleep problems in people with or at risk of psychosis, or (b) subjective experiences of this treatment. Articles not published in peer-review journals were excluded. Treatment effectiveness was investigated for sleep, psychosis and other clinical outcomes. Acceptability was evaluated using qualitative data, drop-out rates, adverse events and relevant questionnaires. Adaptations to standard treatment protocols were described. Research quality was appraised using Cochrane Risk of Bias tools for randomised and non-randomised trials, and a checklist was developed for qualitative papers.

## Results

Of the 975 records identified, 14 were eligible. The most

common CBT target was insomnia. Treatment protocols were typically adapted by omitting sleep restriction. Large effect sizes were reported for sleep outcomes; however, effects for other clinical outcomes were less clear. Qualitative data and acceptability outcomes suggest that treatment was received positively by participants.

## Conclusions

CBT is an effective and acceptable treatment for sleep problems in people with and at risk of psychosis. However, our conclusions are limited by few good-quality studies and small samples. Further gold-standard research is required to inform evidence-based guidelines.

## Keywords

Systematic review; cognitive-behavioural therapy; psychosis; schizophrenia; sleep.

## Copyright and usage

© The Author(s), 2025. Published by Cambridge University Press on behalf of Royal College of Psychiatrists. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.

Sleep problems are commonly reported in psychotic spectrum disorder patients.<sup>1</sup> Traditionally, sleep problems have been viewed as secondary to mental distress, with troubling thoughts, feelings and physiological hyperarousal seen as responsible for keeping people awake.<sup>2</sup> However, recent evidence suggests that sleep difficulties and psychotic symptoms are bidirectionally related.<sup>3</sup> Freeman's cognitive model identifies sleep problems as a causal factor in the development and maintenance of paranoia.<sup>4,5</sup> Lack of sleep can increase anomalous perceptual experiences, such as hearing voices or seeing figures (i.e. hallucinations), which may subsequently be misinterpreted in line with threatening delusional beliefs.<sup>6,7</sup> Sleep deprivation is linked to negative emotion, mood dysregulation and poorer reasoning, which may limit processing of alternative explanations and maintain a sense of threat.<sup>8–10</sup> Nightmares are also hypothesised to maintain persecutory beliefs by interrupting sleep and triggering feelings of threat and negative affect upon waking. Moreover, nightmares typically depict paranoid fears (e.g. physical assault) in vivid detail which may be mistaken for reality, rather than a dream, and may directly reinforce patients' worst fears.<sup>11</sup> Of note, it is not only psychotic symptoms that can be exacerbated by poor sleep. There are wide-ranging consequences for people's daytime functioning, work, family and social relationships.<sup>12</sup> Accordingly, poor sleep is linked to an overall reduced quality of life.<sup>13</sup> It increases susceptibility to developing other mental disorders such as depression and anxiety, and has strong associations with suicidal ideation.<sup>14,15</sup>

## Cognitive-behavioural therapy (CBT) for sleep problems in psychosis

Sleep difficulties are increasingly identified as an important target for treatment. Patients with psychosis report desiring this support.<sup>16,17</sup> Cognitive-behavioural therapy for insomnia (CBT-I) is the first-line recommended treatment for difficulties falling and staying asleep.<sup>18</sup> Sleep is largely regulated by two processes, a homeostatic system ('sleep pressure') and a circadian timing system (circadian rhythms).<sup>19</sup> Sleep pressure rises with waking and falls during sleep and correlates with alertness. Circadian rhythms are directly influenced by environmental cues, especially light, by which they are entrained to a day-night cycle. CBT-I draws from this theory to modify dysfunctional behaviours and beliefs, with the premise that thoughts, feelings and behaviours are linked.<sup>20</sup> For example, people with insomnia may believe they need to nap during the day to catch up on missed sleep. However, this makes it harder to fall asleep at night and leads to a vicious cycle. People may be encouraged to identify and challenge these unhelpful cognitions and reduce napping so that sleep pressure reaches a maximum at night-time. For nightmares, imagery rescripting treatment (IRT) is advised in best practice guidelines.<sup>21,22</sup> IRT is a CBT technique that uses imagery-based techniques to reimagine nightmares with alternative, less threatening endings.<sup>23</sup>

There is growing interest in whether CBT for sleep problems can alleviate psychotic symptoms and prevent clinically high-risk individuals from developing full-blown psychosis. Several trials

have shown promising results.<sup>24–37</sup> Strict adherence to the CBT-I protocol involves elements of sleep restriction and setting a consistent sleep window, which is associated with side-effects such as sleep deprivation, fatigue and impaired vigilance.<sup>38</sup> There is evidence that sleep deprivation can be associated with psychotic symptoms in healthy controls.<sup>39</sup> Studies therefore describe making adaptations to facilitate engagement and mitigate risks of exacerbating patients’ symptoms in the context of psychosis.<sup>17, 24–27,29,30,32–35,37</sup>

Review questions

This review seeks to address the following:

- (a) What are the elements of CBT for sleep problems in people with or at high risk of psychosis-related disorders, and what adaptations are made to facilitate engagement and maximise effectiveness?
- (b) What is the effectiveness in terms of sleep-related outcomes and psychotic symptoms (including delusions and hallucinations)?
- (c) What are the effects on other clinical outcomes, such as depression, anxiety and quality of life?
- (d) What is the acceptability of treatment?

Method

Search strategy and selection criteria

This review adhered to the updated version of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. It was pre-registered on PROSPERO (ID CRD42023434097)<sup>40,41</sup> and was later updated to include the addition of qualitative studies. A systematic search was performed across Embase, Medline, PsycInfo and PubMed for articles published from inception to 12 December 2024. The search terms aimed to capture three main concepts: (a) sleep disorders (e.g. insomnia and nightmares), (b) CBT treatments and (c) psychosis (e.g. symptoms and diagnoses). Keyword searching of titles, abstracts and medical subject headings (MeSH) was undertaken following consultation with a librarian (see Supplementary Material for search terms, available at <https://doi.org/10.1192/bjp.2025.86>). Several research groups were contacted to find out if they were intending to publish any new articles that would be relevant. The decision was made to include non-randomised studies because of the low numbers of randomised controlled trials investigating CBT for sleep problems in people with psychosis.

Screening was performed by two trainee clinical psychologists (H.W., first reviewer; R.B., second reviewer). Papers were excluded if they did not meet the criteria presented in Table 1. After searching across the databases, the studies were first screened using their titles and abstracts. The second reviewer screened 20% of these. Cohen’s kappa<sup>42</sup> showed an almost perfect level of agreement ( $k = 0.85$ ), and disagreements were resolved by discussion.


At the next stage, the first reviewer screened eligible papers at the full-text level and the second researcher screened 25% of these. There was a perfect level of agreement ( $k = 1$ ). Reference lists of included papers were searched to identify any further relevant studies. The study selection process is shown in Fig. 1.

Data extraction and synthesis

Data were systematically extracted by the first reviewer starting on 30 October 2023. The second reviewer independently extracted 50% of the data to ensure accuracy and reliability. Information was gathered regarding publication date, study design, treatment focus, protocol adaptations, geographical location, participant demographics, drop out, adverse events, means and standard deviations of clinical outcomes and questionnaire outcomes pertaining to treatment acceptability or satisfaction. Supplementary materials were checked for additional clinical outcomes that were not reported in the main papers. For trials comparing clinical outcomes across a treatment and control group, Cohen’s  $d$  standardised between-group effect sizes were calculated.<sup>43</sup> For uncontrolled trials, only the direction of the effect was reported since precise estimates were unlikely to be reliable because of the lack of a control group.

Previous research has defined and assessed ‘acceptability’ using a variety of different means. Sekhon et al’s<sup>44</sup> systematic review devises a theoretical framework of intervention acceptability comprising seven components: affective attitude, burden, perceived effectiveness, ethicality, intervention coherence, opportunity costs and self-efficacy. This review attempted to capture acceptability using a multifaceted approach. Themes and quotes that related to these constructs were extracted from qualitative studies by the first author (H.W.). Since there were only two studies, no formal analytic procedure was used; instead, common ideas and quotes were organised into themes, and two supervisors (A.L.-Z. and L.C.J.) were consulted to check their credibility. Drop-out was defined in this review as the number of participants who discontinued after having attended at least one session, during the intervention period.<sup>45</sup> A narrative synthesis was used to interpret these findings together with data from drop-out rates, adverse events and relevant questionnaires.

Table 1 Summary of inclusion criteria	
Dimension	Inclusion criteria
General	Peer-reviewed study evaluating a CBT-based intervention, published in English. This includes controlled or non-controlled trials of an intervention, or qualitative analyses of participants’ experiences of the intervention.
Population	At least a third <sup>a</sup> of participants have a formally diagnosed psychotic disorder or are formally assessed as meeting the criteria for ‘at risk mental state’. Participants present with a level of sleep difficulties that are not caused by a medical sleep disorder (e.g. obstructive sleep apnoea) or neurodegenerative disease (e.g. dementia).
Intervention	CBT-based interventions target sleep problems such as insomnia (i.e. difficulties falling asleep, staying asleep, early waking), nightmares or excessive sleeping.
Comparator/control	There are a minimum of ten participants in experimental studies. There is no minimum number for qualitative studies.
Outcome	Quantitative studies compare outcomes pre- and post-treatment, and/or across a comparison group (if present). Qualitative studies do not need a control group. Quantitative studies assess sleep quality and/or psychotic symptoms and report overall intervention effects. Qualitative studies describe participants’ subjective experiences of engaging in treatment.
CBT, cognitive-behavioural therapy. a. The criteria of a third of participants with psychotic disorder or at-risk mental state were chosen because of the lack of research in this area and seeking to be as inclusive as possible of papers that had the potential to be clinically relevant.	



**Fig. 1** PRISMA flowchart of the study selection process. The reason given for the exclusion of studies reflects the first criterion for exclusion that the author identified. It is possible that some studies met several criteria for exclusion.

### Quality appraisal

The Revised Cochrane ‘Risk of Bias’ (RoB)<sup>46</sup> tool was used to assess all randomised controlled trials (RCTs). The Cochrane ‘Risk of Bias In Non-randomised Studies – of Interventions’ (ROBINS-I)<sup>47</sup> tool was used to assess risk of bias in the remaining non-randomised controlled trials (non-RCTs). These tools yield a risk of bias judgement across several domains (e.g. selection of participants) and for the overall paper. To appraise the quality of qualitative studies, a checklist was developed from Braun and Clarke’s guidelines for reviewers to assess the rigour of thematic analysis.<sup>48</sup>

The second researcher independently appraised 30% of papers after calibrating their ratings with one of each kind of paper (RCT, non-RCT and qualitative). In previous research, both Cochrane tools have demonstrated slight interrater agreement for the overall final judgement of risk of bias and poor-to-moderate agreement for single domains.<sup>49–51</sup> The current review found perfect agreement ( $k = 1$ ) both overall and at the level of single domains for the RoB. Agreement was perfect ( $k = 1$ ) overall and fair ( $k = 0.60$ ) at the level of single domains for the ROBINS-I. Agreement was moderate ( $k = 0.76$ ) on the qualitative quality checklist. Differences between the reviewers were resolved through discussion.

The ‘Measurement Tool to Assess systematic Reviews 2’ (AMSTAR)<sup>52</sup> was used to evaluate the quality of the overall review (see Supplementary Material).

### Results

Fourteen studies were identified as eligible for inclusion. The results are organised by (a) study characteristics, (b) quality appraisal, (c) treatment effectiveness and (d) treatment acceptability.

#### Study design, participant and intervention characteristics

##### Study design and participants

The study and participant characteristics are shown in Table 2. The majority (57.1%) of studies were conducted in the UK with the remainder being conducted in the USA, Spain, South Korea and Australia. There were five RCTs, seven non-RCTs and a mixed-methods study combining a non-RCT and qualitative design. There was also a qualitative paper that used thematic analysis to

**Table 2** Study design and participants

Study	Design	CBT target	Location	Population/clinical presentation	Participants	
					Intervention	Control
Batalla-Martin et al <sup>37</sup>	RCT	Insomnia	Spain	Adults with schizophrenia diagnoses and mild-to-severe insomnia	<i>N</i> = 20; M(age) 50.3 (s.d. = 11.2); Gender: Female 40%, Male 60%; Ethnicity: Not reported	<i>N</i> = 20; M(age) 50.4 (s.d. = 12.8); Gender: Female 40%, Male 60%; Ethnicity: Not reported
Freeman et al <sup>24</sup>	RCT	Insomnia	UK	Adults with schizophrenia, schizoaffective or delusional disorder, with persistent hallucinations or delusions and insomnia	<i>N</i> = 24; M(age) 39.6 (s.d. = 11.6); Gender: Female 33%, Male 67%; Ethnicity: White 92%, Black 4%, Chinese 4%	<i>N</i> = 26; M(age) 42.4 (s.d. = 13.5); Gender: Female 31%, Male 69%; Ethnicity: White 96%, Black 4%
Sheaves et al <sup>25</sup>	RCT	Insomnia	UK	Adults admitted to an in-patient unit for acute mental health crisis with mixed psychiatric diagnoses, including schizophrenia spectrum and other psychotic disorders 45%, with insomnia symptoms	<i>N</i> = 20; M(age) 40 (s.d. = 12); Gender: Male 100%; Ethnicity: Black African 10%, Asian 10%, Mixed ethnic group 5%, White British 60%, White other 15%	<i>N</i> = 20; M(age) 40 (s.d. = 14); Gender: Male 100%; Ethnicity: Asian 5%, Mixed ethnic group 5%, White British 75%, White other 15%
Sheaves et al <sup>26</sup>	RCT	Nightmares	UK	Adults with schizophrenia, schizoaffective disorder, delusional disorder or psychosis not otherwise specified, with current persecutory delusions and nightmares	<i>N</i> = 12; M(age) 43 (s.d. = 12); Gender: Female 42%, Male 58%; Ethnicity: White British 83%, Mixed/ multiple ethnic groups (White and Black African) 8%, Black Caribbean 8%	<i>N</i> = 12; M(age) 39 (s.d. = 13); Gender: Female 42%, Male 58%; Ethnicity: White British 75%, Other 8%, Asian/Asian British – Indian 8%, Asian/Asian British – Pakistani 8%
Waite et al <sup>27</sup>	RCT	Insomnia	UK	Young people at ultra-high risk of psychosis with insomnia	<i>N</i> = 21; M(age) 17.0 (s.d. = 2.2); Gender: Female 52%, Male 48%; Ethnicity: Black British 5%, Black Caribbean 5%, Other 10%, White 81%	<i>N</i> = 19; M(age) 16.8 (s.d. = 2.8); Gender: Female 42%, Male 47%, Other 11%; Ethnicity: Indian 5%, Other 11%, Pakistani 5%, White 79%
Hwang et al <sup>28</sup>	Non-randomised trial with control group	Insomnia	South Korea	Adults with schizophrenia with persistent hallucinations or delusions, and insomnia	<i>N</i> = 31; M(age) 45.7 (s.d. = 10.5); Gender: Female 48%, Male 52%; Ethnicity: Not reported	<i>N</i> = 32; M(age) 44.2 (s.d. = 11.0); Gender: Female 22%, Male 78%; Ethnicity: Not reported
Bradley et al <sup>29</sup>	Case series	Insomnia	UK	Young people at ultra-high risk of psychosis with insomnia or other sleep problem	<i>N</i> = 12; M(age) 18.5 (s.d. = 1.9); Gender: Female 65%, Male 45%; Ethnicity: White 91%, Other 9%	None
Haynes et al <sup>30</sup>	Single-arm trial	Insomnia	USA	Veterans on an in-patient unit, the majority of whom met the clinical threshold for moderate-to-severe insomnia, with mixed psychiatric diagnoses, including schizophrenia 28%, psychosis not otherwise specified 14%	<i>N</i> = 19; M(age) 51.6 (s.d. = 12.2); Gender: Female 5%, Male 95%; Ethnicity not reported	None
Holmes et al <sup>31</sup>	Single-arm trial	Insomnia/sleep quality	USA	Adults with mixed psychiatric diagnoses, including schizophrenia 44%, schizoaffective disorder 11%, with sleep difficulties identified using sleep logs	<i>N</i> = 18; M(age) 34.3 (s.d. = 9.49); Gender: Female 50%, Male 50%; Ethnicity: African American 55%, Other 45%	None
Myers et al <sup>32</sup>	Case series	Insomnia	UK	Adults with schizophrenia, psychotic disorder, psychosis, schizoaffective disorder or delusional disorder, with persistent persecutory delusions and sleep difficulties	<i>N</i> = 15; M(age) 45.5 (s.d. = 11.3); Gender: Female 40%, Male 60%; Ethnicity: White 47%, Black Caribbean 7%, Black African 13%, Black other 20%, Other 13%	None

(Continued)

Novak et al <sup>33</sup>	Single-arm trial	Insomnia	USA	Adults on an in-patient unit with mixed psychiatric diagnoses, either paranoid schizophrenia, psychosis or depressive disorder, and problematic insomnia	N = 13; Age, gender and ethnicity not reported	None
Waters et al <sup>34</sup>	Secondary analysis of a non-randomised trial with control group	Insomnia	Australia	Adults with sleep difficulties and diagnosed non-organic psychotic disorder, including schizophrenia, schizoaffective disorder, bipolar disorder, major depression with psychotic features and psychosis not otherwise specified	N = 50; M(age) 41.2 (s.d. = 10.9); Gender: Female 46%, Male 54%; Ethnicity: Not reported	Not reported
Taylor et al <sup>35</sup>	Single-arm trial and qualitative research (mixed methods)	Insomnia	UK	Adults with schizophrenia spectrum diagnosis and current sleep difficulties	N = 14 for trial; N = 10 for participants taking part in qualitative interviews; M(age) 35.6 (s.d. = 10.9); Gender: Female 36%, Male 64%; Ethnicity: Asian/Asian British 14%, Black/African/Caribbean/Black British 43%, Mixed ethnic group 14%, Other 7%, White 21%	None
Waite et al <sup>33</sup>	Qualitative research	Insomnia	UK	Young people at ultra-high risk of psychosis, who had partaken in Bradley et al's CBT-I intervention <sup>29</sup>	N = 11; M(age) 18.3 (s.d. = 2.0); Gender: Female 55%, Male 45%; Ethnicity: Asian 9%, White 91%	None

CBT, cognitive-behavioural therapy; RCT, randomised controlled trial; CBT-I, cognitive-behavioural therapy for insomnia. This table presents all studies that are included in the review, both qualitative and quantitative. Studies are ordered by type (RCTs, non-randomised trials with a control group, single-arm trials, mixed methods, qualitative). N, number of participants; M(age), mean age of participants; where possible data is reported to one decimal place. All papers reported meeting the inclusion criteria of a third of participants having a psychotic disorder or at-risk mental state. The only exception was Novak et al<sup>33</sup> where it was confirmed in an email from one of the authors that 66% of participants had a diagnosed psychotic disorder (S. Watson, personal communication, January 2025).

understand participants' experiences of treatment in one of the non-RCTs.<sup>29,53</sup>

The total number of participants was 398 across trials (RCT and non-RCT studies) and 21 across qualitative studies. The average age of participants ranged from 18.5 to 51.6 years. Participants were mostly adults with a diagnosed psychotic disorder; however, three studies recruited young people aged 14–25 years who were at risk of developing psychosis.<sup>27,29,53</sup> All participants received CBT-I, except in one study where nightmares were the focus of treatment.<sup>26</sup> All studies had a relatively even split between males and females, excepting one with only male participants<sup>25</sup> and another study of USA veterans<sup>30</sup> in which most of the participants were also male.

It was challenging to summarise ethnicity and race because of a lack of consistency in the categories used. Where this information was reported, studies indicated that the highest proportion of participants identified as White, except for one study where participants predominantly identified as African American<sup>31</sup>; 35.7% of studies did not report ethnicity or race.

Elements of CBT and adaptations

Table 3 gives an overview of the interventions. Standard components of CBT-I protocols include psychoeducation, stimulus control, sleep hygiene (e.g. avoiding screen use before bed), relaxation, worry-management and techniques that address circadian rhythm disruption, such as sleep/wake cycle realignment and daily activity.<sup>20,54</sup> The studies that used CBT-I either explicitly described these elements, or reported following specific protocols that were known to feature them. Boosting daily activity was described as a key feature of several protocols because many psychotic patients have sedentary lifestyles. One study described greater scaffolding, for example, by first educating patients about the efficacy of CBT-I to enhance their motivation to engage, and by linking in with community resources to increase opportunities for structured activity and social connection.<sup>37</sup> Interventions in young people made further adjustments for the social, biological and environmental differences between adolescents and adults (e.g. involving parents, if appropriate).<sup>27,29</sup> Only one study investigated IRT for nightmares.<sup>26</sup> They also incorporated strategies for limiting worry, sleep window stabilisation, relaxation and grounding.

Interventions were delivered in a variety of settings, formats and timeframes. Most interventions took place within a community mental health setting, although three took place on a psychiatric ward.<sup>25,30,33</sup> The majority were delivered by clinical psychologists (53.8%) and as one-to-one sessions (53.8%). The number of intended sessions ranged from four to eight and typically occurred on a weekly basis. One study differed by providing sessions more intensively within a 2-week period to ensure participants received the specified dose before being discharged from acute in-patient admission.<sup>25</sup> Of note, one study reported outcomes after participants received only one or two sessions of a four-session programme because they were limited by the duration of participants' in-patient admission.<sup>30</sup>

The most common adaptation was omitting formal sleep restriction from CBT-I protocols (66.7% of CBT-I studies). Other adaptations included addressing problems of delusions and hallucinations interfering with sleep, oversleeping to escape from psychotic experiences such as voices and fears of going to bed caused by past adverse experiences.

Quality appraisal

Table 4 shows risk of bias ratings for RCT and non-RCT studies. Four RCTs were rated as low risk across all the Cochrane domains because of rigorous procedures in their design and analysis.<sup>24–27</sup>



**Table 3** Elements of cognitive-behavioural therapy (CBT) and adaptations

Study	Delivery/ format	Adaptations to standard CBT				
		Omit sleep restriction	Address delusions or hallucinations	Address oversleeping to escape psychosis	Address fear of bed	Address nightmares
Batalla-Martin et al <sup>37**</sup>	6 × 1.5 h group CBT-I sessions led by a nurse.	–	–	–	–	–
Freeman et al <sup>24</sup>	8 × 1 h individual CBT-I sessions led by clinical psychologist.	X	X	X	X	X
Sheaves et al <sup>25</sup>	Minimum 5 × 1 h individual CBT-I sessions led by clinical psychologist.	X	X	–	–	–
Sheaves et al <sup>26**</sup>	4 × 1 h individual sessions involving CBT for nightmares led by clinical psychologist. Image rehearsal therapy was the key technique offered to all participants.	–	X	–	–	N/A
Waite et al <sup>27</sup>	8 × 1 h individual CBT-I sessions led by clinical psychologist.	X	X	–	–	X
Hwang et al <sup>28*</sup>	4 × 45 min group CBT-I sessions led by mental health social worker trained in CBT.	–	–	–	–	–
Bradley et al <sup>29</sup>	8 × 1 h individual CBT-I sessions led by clinical psychologist.	X	–	–	–	–
Haynes et al <sup>30**</sup>	Attendance of any 1 or 2 × 1 h group sessions out of a 4-session rolling CBT-I programme. Led by clinical psychologist.	X	–	–	–	–
Holmes et al <sup>31*</sup>	4 group sessions of a sleep management training class incorporating CBT-I principles. Length and therapist qualifications not reported.	–	–	–	–	–
Myers et al <sup>32*</sup>	4 × 1 h individual CBT-I sessions led by clinical psychologist.	–	–	–	–	–
Novak et al <sup>33**</sup>	Small group CBT-I; session number, length and lead therapist qualifications not reported.	X	X	–	–	–
Waters et al <sup>34**</sup>	4 × 1.5 h group CBT-I sessions led by a trained psychology student.	X	X	–	–	X
Taylor et al <sup>35</sup>	6 × 30 min sessions delivered by mobile app. Support available from a trainee clinical psychologist.	X	X	–	–	–

CBT-I, cognitive-behavioural therapy for insomnia; CBT, cognitive-behavioural therapy.  
 'X' indicates that this adaptation was made to treatment. Papers have been marked by a single asterisk (\*) where an attempt was made to contact their authors to clarify further details about adaptations, but contact was not achieved. Papers have been marked by a double asterisk (\*\*) where the authors responded to enquiries.  
 Waite et al's paper<sup>27</sup> is not included here since it is a qualitative analysis of participants in Bradley et al's trial,<sup>29</sup> and thus reports the same intervention.  
 Studies are presented in order of type (randomised controlled trials, non-randomised trials with a control group, single-arm trials, mixed methods, qualitative).

**Table 4** Cochrane Risk of Bias (RoB) appraisal of randomised and non-randomised trials

RCT studies	Randomisation	Deviations from interventions	Missing outcome data	Measurement of outcome	Selection of result	Overall risk of bias
Batalla-Martin et al <sup>37</sup>	Low	Low	Low	Some concerns	Low	Some concerns
Freeman et al <sup>24</sup>	Low	Low	Low	Low	Low	Low
Sheaves et al <sup>25</sup>	Low	Low	Low	Low	Low	Low
Sheaves et al <sup>26</sup>	Low	Low	Low	Low	Low	Low
Waite et al <sup>27</sup>	Low	Low	Low	Low	Low	Low

Non-RCT studies	Confounding	Selection of participants	Intervention classification	Deviations from interventions	Missing outcome data	Measurement of outcome	Selection of result	Overall risk of bias
Hwang et al <sup>28</sup>	Moderate	Moderate	Low	Low	Low	Low	Low	Moderate
Bradley et al <sup>29</sup>	Serious	Serious	Low	Low	Low	Moderate	Low	Serious
Haynes et al <sup>30</sup>	Critical	Critical	Low	Serious	Critical	Moderate	Low	Critical
Holmes et al <sup>31</sup>	Serious	Serious	Low	No information	Low	Serious	Serious	Critical
Myers et al <sup>32</sup>	Serious	Serious	Low	Low	Low	Moderate	Low	Serious
Novak et al <sup>33</sup>	Critical	Serious	Low	No information	Critical	Moderate	Low	Critical
Waters et al <sup>34</sup>	Serious	Serious	Low	Low	Critical	Moderate	Moderate	Critical
Taylor et al <sup>35</sup>	Serious	Serious	Low	Moderate	Serious	Moderate	Low	Critical

Studies are grouped by whether they are randomised controlled trials (RCTs) or non-randomised trials (non-RCTs). Non-RCTs are further ordered by type (controlled, single arm, mixed methods).  
 The Cochrane 'Risk of Bias' (RoB) tool was used to assess RCTs and the Cochrane 'Risk of Bias In Non-randomised Studies – of Interventions' (ROBINS-I) tool was used to assess non-RCTs. Both tools rate studies based on their risk of bias across specific domains and overall. The RoB rates each study using three categories: low, some concerns or high risk of bias. The ROBINS-I tool rates the risk of bias for each study using five categories: low, moderate, serious, critical or no information.

Strengths included that they were pre-registered and used blinded assessors. One RCT was evaluated as having 'some concerns' because assessment was not blinded.<sup>37</sup> The non-RCTs fell almost entirely into 'serious' and 'critical' categories. Their greatest area of weakness was the potential for confounding. All studies but two lacked a control group,<sup>28,34</sup> and of these two, only one attempted to deal with confounding by controlling for differences in baseline characteristics between the treatment and control group.<sup>28</sup> This study was also the

only non-RCT to be use a blinded assessor and hence to be rated as 'low' on the domain of outcome measurement.<sup>28</sup>

Another area of weakness in the non-RCTs was the selection of participants. Without random assignment to a control, bias was likely introduced by participants self-selecting into the study or being selected by clinicians. Risk of bias caused by missing data was highly variable across the non-RCTs; while several studies reported zero drop-out, two studies had critically high levels of drop-out,

**Table 5** Effect of cognitive-behavioural therapy (CBT) on sleep problems

Study	Risk of bias	Primary outcome	Post-treatment; <i>d</i> , CI 95%	Follow-up; <i>d</i> , CI 95%
Batalla-Martin et al <sup>37</sup>	Some concerns	ISI	1.46 [0.63, 2.29]	3 months 1.98 [1.01, 2.94]
Freeman et al <sup>24</sup>	Low	ISI	1.32 [0.58, 2.05]	3 months 0.82 [0.18, 1.46]
Sheaves et al <sup>25</sup>	Low	ISI	0.92 [0.20, 1.63]	2 weeks 0.79 [0.08, 1.50] 10 weeks 0.75 [0.01, 1.51]
Sheaves et al <sup>26</sup>	Low	DDNSI	0.95 [−0.04, 1.93]	1 month 1.07 [−0.04, 2.17]
Waite et al <sup>27</sup>	Low	ISI	1.96 [0.99, 2.93]	3 months 1.27 [0.47, 2.07]
Hwang et al <sup>28*</sup>	Moderate	ISI	Calc: 9.42 [6.68, 12.15]* Rep: 0.5, <i>p</i> < 0.001	1 month Calc: 9.96 [7.07, 12.85]* Rep: 0.5, <i>p</i> < 0.001
Bradley et al <sup>29</sup>	Serious	ISI	<i>d</i> > 0	1 month <i>d</i> > 0
Haynes et al <sup>30</sup>	Serious	ISI	<i>d</i> > 0	1 month <i>d</i> > 0
Holmes et al <sup>31</sup>	Critical	ISI	<i>d</i> > 0	None
Myers et al <sup>32</sup>	Critical	Subjective sleep rating	<i>d</i> > 0	None
Novak et al <sup>33</sup>	Critical	ISI	<i>d</i> > 0	None
Waters et al <sup>34</sup>	Critical	PSQI	<i>d</i> > 0	None
Taylor et al <sup>35</sup>	Critical	ISI	<i>d</i> > 0	None

This table reports the effect of CBT in alleviating sleep problems as assessed by the primary sleep measure. Studies are organised by their risk of bias category, from low to increasingly severe.  
Cohen's *d* between-group effect sizes are shown for controlled studies, whereas the direction of the effect (pre-treatment versus post-treatment) is simply shown for uncontrolled studies. Results have been transformed such that an improvement in sleep problems in the treatment group (relative to the control group, if present) over the course of treatment is represented by a positive change score (i.e. *d* > 0). A deterioration in sleep problems in the treatment group (relative to a control group, if present) is represented by a negative score (i.e. *d* < 0). The text in brackets refers to the 95% confidence interval of the effect size.  
For Hwang et al's study,<sup>28</sup> 'Calc' refers to the Cohen's *d* effect size calculated from their reported means and standard deviations, whereas 'Rep' refers to the Cohen's *d* effect size reported in their paper. The asterisk (\*) indicates the need to treat their findings with caution given the large discrepancy between these estimates.  
Primary measures include the following: ISI, Insomnia Severity Index;<sup>35</sup> DDNSI, Disturbing Dream and Nightmare Severity Index;<sup>36</sup> and PSQI, Pittsburgh Sleep Quality Index.<sup>57</sup> Holmes et al<sup>31</sup> report a subjective sleep rating that is extracted from a sleep log published elsewhere<sup>58</sup> but provide minimal further details. Where studies did not specify a single primary sleep measure, the most relevant measure to evaluate the intervention (e.g. an insomnia measure for a study of cognitive-behavioural therapy for insomnia) is reported.

presumably reflecting the lack of control in the acute in-patient setting regarding patients' prognosis and discharge.<sup>30,33</sup> These two studies also suffered greater potential for confounding where it was likely that patients were receiving psychiatric stabilisation and medication changes alongside CBT-I.<sup>30,33</sup>

Checklist ratings for the two qualitative thematic analyses<sup>35,53</sup> are found in the Supplementary Material. A strength they shared was that themes were well evidenced and gave rise to actionable outcomes – they highlighted participants' experiences of CBT-I, which led to practical implications for how treatment could be improved. However, neither paper specified what kind of thematic analysis was used or explained their theoretical orientation. The authors also did not 'own their perspectives' regarding their social and personal positioning, which was arguably important where they were representing the voices of a marginalised group to which they may not have belonged.

## Treatment effectiveness<sup>a</sup>

### Sleep problems

Table 5 shows the effectiveness of targeting sleep problems using the primary sleep measure, with studies organised by their risk of bias category rating. The sign of effect sizes has been changed such that a positive effect (*d* > 0) indicates an improvement in symptoms over the course of treatment. If the study includes a control group, a positive effect size indicates a relative improvement in symptoms in the treatment group compared to the control.

Most studies (76.9%) chose the Insomnia Severity Index (ISI)<sup>55</sup> as their primary measure, whereas other studies chose to measure sleep quality or nightmares. Every study demonstrated positive effects, suggesting improvement in sleep problems following

treatment. Effect sizes were calculated for studies with a control group, and ranged from medium to very large immediately post-intervention (*d* = 0.50–1.96). These calculated effects were all significant (i.e. confidence intervals did not overlap zero), except for one study<sup>26</sup> where the lower boundary of the wide confidence interval was marginally negative. This was the smallest RCT (only 12 participants in each group) and was likely underpowered. It was also the only study to investigate IRT, as opposed to CBT-I, and its primary outcome was the Disturbing Dreams and Nightmares Severity Index (DDNSI)<sup>56</sup> (a measure of nightmare frequency and severity), which may not be directly comparable to the other studies whose primary outcomes were sleep quality and insomnia. Over follow-up periods, effect sizes were broadly maintained (*d* = 0.50–1.98), with the longest follow-up taking place at 3 months.

### Psychotic symptoms

The impact of CBT-I on psychosis is presented in Table 6. Psychosis was assessed in nine trials using a variety of measures relating to delusions, hallucinations and other symptoms. The effects were almost entirely positive, in the direction suggesting a relative improvement of symptoms. Indeed, most studies reported solely positive results (66.7%); however, three of the studies found a mixed direction of effects across multiple measures or time-points.<sup>24,25,27</sup>

Calculated effect sizes ranged between *d* = −0.39 and *d* = 0.79 across post-intervention and between *d* = −0.39 and *d* = 0.79 across follow-up and confidence intervals were generally very wide, which suggests high levels of uncertainty around these estimates. These effects were almost entirely non-significant since confidence intervals overlapped zero.

### Other clinical outcomes

Ten trials evaluated whether CBT-I led to clinical improvements beyond sleep and psychosis. The most commonly assessed domains were anxiety, depression, quality of life and well-being. Table 7 displays effect sizes where a positive sign denotes a relative improvement in outcomes following treatment. Most effect sizes were positive, suggesting that participants' outcomes improved.

<sup>a</sup> Of note, ranges of effect size presented in the text of this section exclude Hwang et al's figures.<sup>28</sup> This is because the effect sizes that we calculated (from their reported means and standard deviations) were extremely large and did not match what was reported in their paper. The authors were contacted about this, but no response was received. It was observed that their reported standard deviations were unusually small, and it was queried whether they were possibly reporting standard errors instead. Caution is advised in interpreting Hwang et al's results.

**Table 6** Effect of cognitive-behavioural therapy (CBT) on psychotic symptoms

Study	Risk of bias	Measures	Post-treatment; <i>d</i> , CI 95%	Follow-up; <i>d</i> , CI 95%
Batalla-Martin et al <sup>37</sup>	Some concerns	None		
Freeman et al <sup>24</sup>	Low	PSYRATS (delusions)	0.16 [−0.43, 0.75]	3 months −0.11 [−0.69, 0.47]
		PSYRATS (hallucinations)	−0.33 [−0.93, 0.27]	−0.39 [−0.98, 0.20]
		GPTS	0.21 [−0.39, 0.80]	0.31 [−0.30, 0.92]
		PANSS	0.40 [−0.21, 1.01]	0.35 [−0.27, 0.96]
Sheaves et al <sup>25</sup>	Low	PANSS Total	0.32 [−0.32, 0.97]	2 weeks 0.06 [−0.58, 0.71]
		PANSS (positive symptoms)	0.04 [−0.60, 0.67]	−0.02 [−0.67, 0.63]
		PANSS (negative symptoms)	0.35 [−0.30, 1.00]	0.50 [−0.17, 1.17]
		PANSS (psychopathology)	0.30 [−0.34, 0.95]	10 weeks −0.16 [−0.81, 0.49]
				0.34 [−0.37, 1.05]
				0.19 [−0.51, 0.89]
				0.69 [−0.06, 1.43]
				0.06 [−0.63, 0.76]
Sheaves et al <sup>26</sup>	Low	CAPS	0.03 [−0.86, 0.91]	1 month 0.02 [−0.96, 0.91]
		GPTS	0.72 [−0.24, 1.68]	0.65 [−0.35, 1.65]
Waite et al <sup>27</sup>	Low	CAARMS	0.45 [−0.19, 1.10]	3 months 0.31 [−0.36, 0.97]
		ČEFSA	0.11 [−0.56, 0.79]	0.24 [−0.42, 0.91]
		GPTS-A	0.40 [−0.29, 1.08]	0.68 [−0.02, 1.37]
		GPTS-B	0.36 [−0.33, 1.03]	0.76 [0.06, 1.47]
		SPEQ	−0.05 [−0.70, 0.61]	0.19 [−0.46, 0.84]
Hwang et al <sup>28*</sup>	Moderate	PSYRATS Total	Calc: 2.69 [1.77, 3.61]* Not reported <i>d</i> in paper as $p > 0.1$	1 month Calc: 3.08 [2.07, 4.09]* Rep. 0.1, $p = 0.053$
		PSYRATS (hallucinations)	Calc: 1.26 [0.64, 1.88]* Not reported <i>d</i> in paper as $p > 0.1$	Calc: 1.63 [0.94, 2.31]* Not reported <i>d</i> in paper as $p > 0.1$
		PSYRATS (delusions)	Calc: 2.38 [1.53, 3.22]* Not reported <i>d</i> in paper as $p > 0.1$	Calc: 2.58 [1.69, 3.47]* Not reported <i>d</i> in paper as $p > 0.1$
Bradley et al <sup>29</sup>	Serious	GPTS	$d > 0$	1 month $d > 0$
		SPEQ	$d > 0$	$d > 0$
Haynes et al <sup>30</sup>	Serious	GPTS-A	$d > 0$	1 month $d > 0$
		GPTS-B	$d > 0$	$d > 0$
		PSYRATS	$d > 0$	$d > 0$
		CAPS	$d > 0$	$d > 0$
Holmes et al <sup>31</sup>	Critical	None		
Myers et al <sup>32</sup>	Critical	None		
Novak et al <sup>33</sup>	Critical	None		
Waters et al <sup>34</sup>	Critical	MINI-p	$d > 0$	None
Taylor et al <sup>35</sup>	Critical	R-GPTS-A	$d > 0$	None
		R-GPTS-B	$d > 0$	
		SPEQ	$d > 0$	

This table reports the effect of CBT in alleviating symptoms of psychosis. Studies are organised by their risk of bias category, from low to increasingly severe. Cohen's *d* between-group effect sizes are shown for controlled studies, whereas the direction of the effect (pre-treatment versus post-treatment) is simply shown for uncontrolled studies. Results have been transformed such that an improvement in psychotic symptoms in the treatment group (relative to the control group, if present) over the course of treatment is represented by a positive change score (i.e.  $d > 0$ ). A deterioration in psychotic symptoms in the treatment group (relative to a control group, if present) is represented by a negative score (i.e.  $d < 0$ ). The text in brackets refers to the 95% confidence interval of the effect size. For Hwang et al's study,<sup>28</sup> Calc. *d* refers to the Cohen's *d* effect size calculated from their reported means and standard deviations, whereas 'Rep. *d*' refers to the Cohen's *d* effect size reported in their paper. The asterisk (\*) indicates the need to treat their findings with caution given the large discrepancy between these estimates. All reported assessment measures of psychosis in each paper are presented. Brackets denote subscales in the measures column of the table; for example, 'PSYRATS (delusions)' refers to the delusions subscale of the PSYRATS. Psychotic measures include the following: Cardiff Anomalous Perceptions Scale (CAPS)<sup>59</sup>; Černis Felt Sense of Anomaly (ČEFSA)<sup>60</sup>; Comprehensive Assessment of At-Risk Mental States (CAARMS)<sup>61</sup>; Green Paranoid Thoughts Scale (GPTS)<sup>62</sup> which contains subscales of 'Ideas of Reference' (GPTS-A) and 'Ideas of Persecution' (GPTS-B); Adapted Mini International Neuropsychiatric Interview – Psychosis section (MINI-p)<sup>63</sup>; Positive and Negative Symptoms Scale (PANSS),<sup>64</sup> which contains subscales relating to positive symptoms, negative symptoms and general psychopathology; Psychotic Symptom Rating Scale (PSYRATS),<sup>65</sup> which contains subscales relating to delusions and hallucinations; Revised-Green Paranoid Thoughts Scale (R-GPTS),<sup>66</sup> which contains subscales of GPTS-A and GPTS-B; Specific Psychotic Experiences Questionnaire (SPEQ).<sup>67</sup>

Nevertheless, these effects were largely non-significant. Confidence intervals were very wide and overlapped zero, suggesting that estimates were quite uncertain.

The magnitude of effect sizes ranged from around zero to very large. The largest positive effect size was  $d = 1.58$  on a measure of functioning at 1-month follow-up.<sup>27</sup> Of note, a large negative effect size of  $d = -0.92$  was obtained on a suicidal ideation subscale at 1-month follow-up.<sup>26</sup> This negative effect size resulted from the control group having a much higher starting mean suicidal ideation at baseline that decreased, whereas the suicidal ideation for the treatment group remained relatively stable from week 0 to week 8.

Across trials, there were a wide variety of outcomes and measures making it relatively challenging to synthesise. Depression and anxiety were measured in seven papers (53.8% of trials). A positive direction

of effects was observed at all time-points immediately post-intervention for depression (range:  $d = 0.31$ – $0.37$ ) and anxiety (range:  $d = 0.41$ – $0.61$ ), suggesting in an improvement in symptoms. These all remained positive at follow-up, except for one study,<sup>26</sup> which found negative effects. At 1 month follow-up the range was  $d = -0.36$  to  $0.67$  for depression, and  $d = -0.06$  to  $0.95$  for anxiety.

Mental well-being was assessed in five papers (38.5% of trials) and, similarly, all effects were positive immediately post-intervention (range:  $d = 0.39$ – $0.56$ ), which suggests that participants' mental well-being improved. They were also positive at follow-up except for one study<sup>26</sup> and ranged from  $d = -0.15$  to  $0.74$ . Finally, effect sizes for changes in quality of life (measured in five papers, representing 38.5% of trials) were all positive except in one study<sup>26</sup> at both post-intervention (range:  $d = -0.39$  to  $0.93$ ) and follow-up (range:  $d = 0$ – $1.46$ ).



**Table 7** Effect of cognitive-behavioural therapy (CBT) on other clinical outcomes

Study	Risk of bias	Measures	Post-treatment; <i>d</i> , CI 95%	Follow-up; <i>d</i> , CI 95%
Batalla-Martin et al <sup>37</sup>	Some concerns	Quality of life (ED-5Q VAS)	0.93 [0.21, 1.65]	3 months 1.38 [0.57, 2.19]
Freeman et al <sup>24</sup>	Low	Psychological recovery (CHOICE)	0.57 [−0.06, 1.19]	3 months 0.26 [−0.35, 0.88]
		Quality of life (ED-5D-5L)	0.57 [−0.06, 1.19]	0.43 [−0.17, 1.04]
		Fatigue (MFI)	0.71 [0.07, 1.35]	0.49 [−0.13, 1.10]
		Mental wellbeing (WEMWBS)	0.41 [−0.20, 1.02]	0.74 [0.09, 1.38]
Sheaves et al <sup>25</sup>	Low	Suicidal ideation (BSS)	0.09 [−0.55, 0.72]	2 weeks −0.03 [−0.67, 0.62]
		Psychological distress (CORE-10)	0.70 [0.02, 1.39]	0.46 [−0.20, 1.13]
		Quality of life (ED-5Q)	−0.39 [−1.04, 0.26]	0 [−0.65, 0.65]
		Mental wellbeing (WEMWBS)	0.39 [−0.27, 1.04]	0.41 [−0.25, 1.07]
		Mania (YMRS)	0.33 [−0.31, 0.98]	0.05 [−0.59, 0.70]
				10 weeks −0.19 [−0.89, 0.51]
				0.28 [−0.43, 0.98]
				0.07 [−0.63, 0.76]
				0.48 [−0.25, 1.20]
				0.42 [−0.29, 1.14]
Sheaves et al <sup>26</sup>	Low	Suicidal ideation (BSS)	−0.44 [−1.36, 0.47]	1 month −0.92 [−1.99, 0.14]
		Anxiety (DASS-21 anxiety)	0.41 [−0.50, 1.32]	−0.06 [−0.99, 0.88]
		Depression (DASS-21 depression)	0.31 [−0.59, 1.20]	−0.36 [−1.31, 0.60]
		Stress (DASS-21 stress)	0.75 [−0.22, 1.71]	−0.16 [−1.10, 0.78]
		Dissociation (DES-B)	0.66 [−0.29, 1.60]	0.36 [−0.60, 1.31]
		Mental wellbeing (WEMWBS)	0.56 [−0.37, 1.50]	−0.15 [−1.09, 0.79]
Waite et al <sup>27</sup>	Low	Suicidal ideation (CSSRS)	0.50 [−0.22, 1.22]	3 months 0.46 [−0.26, 1.18]
		Negative schemas (BCSS-negative)	0.51 [−0.19, 1.21]	0.67 [−0.03, 1.38]
		Positive schemas (BCSS-positive)	0.75 [0.02, 1.48]	0.51 [−0.17, 1.20]
		Anxiety (DASS-21 anxiety)	0.61 [−0.10, 1.33]	0.95 [0.19, 1.71]
		Depression (DASS-21 depression)	0.37 [−0.32, 1.06]	0.67 [−0.04, 1.39]
		Stress (DASS-21 stress)	0.72 [−0.01, 1.45]	0.58 [−0.12, 1.29]
		Worry (DWQ)	0.37 [−0.32, 1.06]	0.98 [0.23, 1.73]
		Quality of life (EQ-5D-5L-Index)	0.36 [−0.33, 1.05]	0.36 [−0.31, 1.03]
		Quality of life (EQ-5D-5L-VAS)	0.43 [−0.26, 1.13]	0.62 [−0.08, 1.32]
		Agoraphobic avoidance (O-AS-A)	0.51 [−0.19, 1.22]	0.58 [−0.12, 1.29]
		Agoraphobic distress (O-AS-D)	0.51 [−0.19, 1.22]	0.84 [0.08, 1.59]
		Depression (PHQ-15)	0.42 [−0.28, 1.11]	0.46 [−0.22, 1.15]
		Recovery (QPR)	0.21 [−0.47, 0.89]	0.33 [−0.34, 1.00]
		Quality of life (ReQoI)	0.81 [0.05, 1.56]	1.46 [0.61, 2.32]
		Functioning (WSAS)	0.87 [0.12, 1.63]	1.58 [0.71, 2.46]
Hwang et al <sup>28</sup>	Moderate	Anxiety (ASI)	Calc: 1.66 [1.00, 2.35] Not reported <i>d</i> in paper as $p > 0.1$	1 month Calc: 2.78 [1.84, 3.72] Not reported <i>d</i> in paper as $p > 0.1$
		Depression (BDI)	Calc: 3.48 [2.37, 4.60] Not reported <i>d</i> in paper as $p > 0.1$	Calc: 4.54 [3.15, 5.93] Not reported <i>d</i> in paper as $p > 0.1$
Bradley et al <sup>29</sup>	Serious	Anxiety (DASS-21 anxiety)	$d > 0$	1 month $d > 0$
		Depression (DASS-21 depression)	$d > 0$	$d > 0$
		Stress (DASS-21 stress)	$d > 0$	$d > 0$
		Mental wellbeing (WEMWBS)	$d > 0$	$d > 0$
		Functioning (WSAS)	$d > 0$	$d > 0$
Haynes et al <sup>30</sup>	Serious	Anxiety (DASS-21 anxiety)	$d > 0$	1 month $d > 0$
		Depression (DASS-21 depression)	$d > 0$	$d > 0$
Holmes et al <sup>31</sup>	Critical	None		
Myers et al <sup>32</sup>	Critical	None		
Novak et al <sup>33</sup>	Critical	None		
Waters et al <sup>34</sup>	Critical	Impulsivity (BIS)	$d > 0$	None
		Quality of life (MANSA)	$d > 0$	
		Anxiety and depression (PHQ-4)	$d > 0$	
Taylor et al <sup>35</sup>	Critical	Anxiety (DASS-21 anxiety)	$d > 0$	None
		Depression (DASS-21 depression)	$d > 0$	
		Stress (DASS-21 stress)	$d > 0$	
		Mental wellbeing (WEMWBS)	$d > 0$	
		Functioning (WSAS)	$d > 0$	

This table reports the effect of CBT in alleviating other clinical symptoms. Studies are organised by their risk of bias category, from low to increasingly severe. Cohen's *d* between-group effect sizes are shown for controlled studies, whereas the direction of the effect (pre-treatment versus post-treatment) is simply shown for uncontrolled studies. Results have been transformed such that an improvement in clinical symptoms in the treatment group (relative to the control group, if present) over the course of treatment is represented by a positive change score (i.e.  $d > 0$ ). A deterioration in clinical symptoms in the treatment group (relative to a control group, if present) is represented by a negative score (i.e.  $d < 0$ ). The text in brackets refers to the 95% confidence interval of the effect size.

For Hwang et al's study,<sup>28</sup> Calc. *d* refers to the Cohen's *d* effect size calculated from their reported means and standard deviations, whereas 'Rep. *d*' refers to the Cohen's *d* effect size reported in their paper. The asterisk (\*) indicates the need to treat their findings with caution given the large discrepancy between these estimates.

The Measures column states the clinical symptom that was assessed, followed by the assessment measure in brackets. Assessment measures include the following: Anxiety Sensitivity Index (ASI)<sup>48</sup>; Barratt Impulsiveness Scale - Brief (BIS)<sup>69</sup>; Brief Core Schema Scale (BCSS)<sup>70</sup>; Beck Depression Inventory (BDI)<sup>71</sup>; Beck Suicide Scale (BSS)<sup>72</sup>; Choice of Outcome in CBT for psychoses (CHOICE)<sup>73</sup>; Clinical Outcomes in Routine Evaluation 10-item scale (CORE-10)<sup>74</sup>; Columbia Suicide Severity Rating Scale (CSSRS)<sup>75</sup>; Depression Anxiety and Stress Scale-21-item (DASS-21)<sup>76</sup> version with subscales for anxiety (DASS-21 anxiety), depression (DASS-21 depression) and stress (DASS-21 stress); Brief Dissociative Experiences Scale (DES-B)<sup>77</sup>; Dunn Worry Questionnaire (DWQ)<sup>78</sup>; Euroqol 5D questionnaire (ED-5Q)<sup>79</sup>; Euroqol 5D questionnaire visual analogue scale (ED-5Q VAS)<sup>79</sup>; Euroqol 5D questionnaire 5 Level version (ED-5D-5L)<sup>80</sup>; Manchester Short Assessment of Quality of Life (MANSA)<sup>81</sup>; Multidimensional Fatigue Inventory (MFI)<sup>82</sup>; Oxford Agoraphobic Avoidance Scale (O-AS)<sup>83</sup> with subscales for avoidance (O-AS-A) and distress (O-AS-D)<sup>84</sup>; Patient Health Questionnaire 15-item version (PHQ-15)<sup>85</sup>; Brief Patient Health Questionnaire (PHQ-4)<sup>84</sup>; Questionnaire about the Process of Recovery (QPR)<sup>86</sup>; Recovering Quality of Life (ReQoI)<sup>87</sup>; Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)<sup>88</sup>; Work and Social Adjustment Scale (WSAS)<sup>89</sup>; Young Mania Rating Scale (YMRS).<sup>90</sup>

Theme	Subtheme	Waite et al (2018) <sup>53</sup> Illustrative quotes	Taylor et al (2022) <sup>35</sup> Illustrative quotes
There were initial negative expectations about CBT-I	Doubts about effectiveness	P8 (F) 'I didn't think it would work at first' P1 (F) 'some people [I'd heard in class], they were just like, oh, just sleep late, just, you know, like hot chocolate, or just count some sheep, and I was like, "Oh, it's just going to be that all over again!"' P2 (M) 'little methods, such as like writing things down, and how actually when you think about that, that seems like it's not really going to do anything'	P10 (M) 'I'm sceptical about this kind of stuff'
	Fear of having a negative experience	P9 (F) 'I was scared that I was going to kind of be judged for like my sleep and stuff' P10 (M) 'my worry was it was just going to be like some depressing. . . fest [laughing]'	–
	Increased awareness of factors affecting sleep	P11 (F) 'it sort of opened. . . well, not opened my eyes as such, but gave me a wider understanding of what actually affects my sleep' P9 (F) 'I learnt quite a lot, and it was just kind of. . . some obvious stuff, but it was said kind of in a way that I hadn't thought about before and I hadn't thought like how it was really affecting my sleep'	P7 (M) 'There wasn't like a set routine for sleep until I learned about how a routine could help'
	Practical skills were acquired	P10 (M) 'I'm using a lot of the techniques that I was given through this'	–
CBT-I helped develop skills for improving sleep	Sleep quality was enhanced	P4 (M) 'I've been falling asleep quicker and spending more time asleep' P3 (F) 'waking up no more than twice during the night and not feeling concerned when I wake up' P7 (F) 'I do sleep now [laughing], at like the proper time'	P1 (F) 'think that my sleep has improved . . . by, I'd say, 40%' P10 (M) 'Yeah, it's been beneficial for me'
	Better sleep was linked to better functioning	P11 (F) 'If I get a decent night's sleep, I'm not tired during the day' P10 (M) 'I had originally thought it was more down to stuff during the day, like how much energy you had used on this activity or this activity or, again, what you're eating, but I didn't realise how much was down to sleep'	P7 (M) 'I can tell the impact in my everyday life . . . in helping take care of the girls. Yeah, I mean in my everyday interaction with people'
	Psychotic and other clinical symptoms showed improvements	P8 (F) 'since I've been sleeping better, my, visual things have like stopped' P3 (F) 'I used to hear things quite a lot, like walking down the street, and that's subsided, almost entirely' P11 (F) 'the depression has been the big step. It's really eased. It's nowhere near where it used to be' P3 (F) 'I suffer from depression so it's not going to be high all the time, but because it's so highly linked with sleep, when I sleep better, I tend to have a better day' P9 (F) 'I find it also has helped my anxiety a lot. I'm able to cope with situations a lot better and kind of stay in control, which I think has come from me gaining control of my sleep a bit'	–
	An interactive and collaborative approach facilitated motivation to engage	P3 (F) '[my therapist] was very happy to work through any other problems that I was having at the same time' P3 (F) '[my therapist] would give me a technique and then I'd come back and say "This worked for me; this didn't work for me", and then we could kind of work around that' P1 (F) 'It is based, like, what you do during the day, diet, social life, like taking all that into account along with your sleep'	P7 (M) 'The fact that there's an app, and there's someone like [trial therapist] to like, keep me in tack or like keep checking up on my progress. I think those, those elements made the experience better for me' P4 (M) '[in discussing a disadvantage of the app] ' . . . if it's a recording of [therapist] tutoring, or [therapist] walking through the steps, I see that more interactive. Because [ . . . ] I see somebody there trying to tell me what to do. I mean it will make more meaning in that sense'

(Continued)

Readily accessible support was valued	P3 (F) 'if I was struggling during the week, I could just email and say, "Having a tough day--any advice?" sort of thing. That was really helpful'	P1 (F) 'The advantage of using the app was it, it's there any time of the today, you can refer to it'
	P5 (M) 'if I sort of felt like I was having sleep problems again, I can go back to this and go, well, here's things I can use'	P6 (F) 'because I'm, I'm not a technical person at all [...], that's the only downside ...'
	P8 (F) 'the booklet things, did confuse me a bit'	P3 (M) 'the amount of work you had to do to get a quick reminder of what you wanna do [...] you'd have to go through quite a bit just to get to the section that you want'
	P3 (F) and P5 (M) 'repetitive'	P6 (F) '...it's quite a lot in a short time'
	P9 (F) 'tedious'	P3 (M) 'it's also a lot to keep doing everyday ...'
	There were limitations to treatment	
	Strategies could be difficult to implement and maintain	
	Effects could be small or unsuccessful	
CBT-I, cognitive-behavioural therapy for insomnia. Themes and subthemes based on the research of Waite et al <sup>33</sup> and Taylor et al <sup>35</sup> with accompanying participant quotes. Participant number and gender are indicated.		

Treatment acceptability

Qualitative evidence

Treatment acceptability was evaluated through several different means. Relevant themes and quotes from two thematic analyses are organised in Table 8.<sup>35,53</sup> When organising themes, a realist philosophical orientation was adopted. Quotes were interpreted literally in relation to the question, ‘what does the data tell us about participants’ experiences of CBT-I treatment?’

Five themes and 12 subthemes were developed from the data. The first theme was ‘initial negative expectations about CBT-I’. It appears that some participants were initially apprehensive about engaging in treatment. They were concerned about being prescribed ‘little methods’ such as counting sheep, and it was hard to see what difference treatment could make. In addition, some participants feared being ‘judged’, and that the content would be ‘depressing’.

The themes ‘CBT-I helped develop skills for improving sleep’ and ‘improved sleep had ripple effects on other areas of life’ show that many participants benefitted from treatment. Participants described learning what factors influenced their sleep and acquiring strategies to enhance their sleep quality. The consequences of better sleep could be widespread. Increased energy allowed them to engage in meaningful tasks, and they noticed improvements in mood, anxiety and psychotic experiences.

Participants also mentioned a theme of ‘limitations’. Strategies were not always successful and could require trial and error. Some strategies demanded high commitment, which could be difficult to maintain long term. These issues related to the theme that ‘the format of CBT-I affected engagement’. Some participants found booklets repetitive to complete<sup>53</sup>; while others found that technical aspects of a mobile app could pose a barrier.<sup>35</sup> Across both studies, participants appreciated when treatment was collaborative and interactive. Participants in one study<sup>53</sup> praised how therapists tailored therapy to accommodate their preferences and lifestyle in one study when sessions were delivered in-person. By contrast, participants in the other study<sup>35</sup> saw the lack of interaction with a therapist as a disadvantage of receiving treatment through a mobile app. Participants in both studies commented on how they valued regular access to support. One study<sup>53</sup> achieved this by allowing participants to email therapists and access workbooks, whereas participants in the other study<sup>35</sup> mentioned the benefits of being able to access resources at any time via the app.

Drop-out and adverse events

Table 9 presents rates of drop-out and adverse events. Drop-out was reported in 76.9% of trial studies. Three studies observed 0% drop-out from treatment.<sup>25,26,32</sup> The highest rates were 25% and 27.8% in two studies that were set in acute in-patient wards and had weaker control for extraneous variables and follow-up with participants.<sup>30,33</sup> Reasons for drop-out were not generally stated, and it was unclear whether any studies sought to follow-up with participants who withdrew to find out the reasons for this.

Adverse events were commonly defined by papers as serious incidents that led to in-patient admission or disability, or were life-threatening. The proportion of participants who had adverse events in the treatment group was slightly numerically higher (7.6% of participants) than in the control (4.8%). However, it is not possible to draw conclusions from this as total numbers were low, and few studies reported this data. All studies deemed adverse events were unrelated to treatment.

Questionnaire data

Three studies offered treatment satisfaction questionnaires. Participants in one study<sup>26</sup> provided therapy satisfaction ratings to an independent assessor regarding their experiences of IRT. The

Table 9 Rates of drop-out and adverse events			
Study	Drop-out (%)	Adverse events	
		Intervention	Control
Batalla-Martin et al <sup>37</sup>	0%	Not reported	–
Freeman et al <sup>24</sup>	8.3%	3 participants (12.5%) had 5 adverse events	0
Sheaves et al <sup>25</sup>	0%	1 participant (5.0%)	0
Sheaves et al <sup>26</sup>	0%	2 participants (16.7%)	1 participant (8.3%)
Waite et al <sup>27</sup>	4.8%	4 participants (19.0%) had 5 adverse events	2 participants (11.0%) had 3 adverse events
Hwang et al <sup>28</sup>	Not reported	Not reported	Not reported
Bradley et al <sup>29</sup>	8.3%	0	–
Haynes et al <sup>30</sup>	25.0%	Not reported	–
Holmes et al <sup>31</sup>	Not reported	Not reported	–
Myers et al <sup>32</sup>	0%	0	–
Novak et al <sup>33</sup>	27.8%	None classed as related to the study but number not stated	–
Waters et al <sup>34</sup>	20.0%	Not reported	Not reported
Taylor et al <sup>35</sup>	15.0%	0	–

median score was 9 out of 10 (interquartile range (IQR) 6.75–10), suggesting high satisfaction. These participants were also given a client satisfaction questionnaire; 56.2% were ‘very satisfied’ and the remainder responded that they were ‘mostly satisfied’. Another study<sup>27</sup> adopted the Abbreviated Acceptability Rating Profile (AARP)<sup>91</sup> to evaluate CBT-I in young people at ultra-high risk of psychosis. The average score was 45.8 (s.d. 4.1) and the median was 48 (IQR 46–68), out of a possible maximum of 48. Participants in the third study<sup>35</sup> used the ‘Experience Feedback Questionnaire’.<sup>92</sup> The proportion of participants who rated the app-based CBT-I intervention as ‘enjoyable to use’ was 81.8%, ‘not disruptive to life’ was 72.7%, ‘not stopping usual activities’ was 81.1%, ‘not embarrassing’ was 100% and ‘easy to remember to use’ was 45.4%.

Discussion

This review addresses several gaps in the research literature regarding the evidence-base for CBT interventions for sleep problems in people with, or at risk of, psychosis. We first summarise the content of these CBT interventions, before proceeding to discuss their clinical effectiveness and acceptability.

CBT interventions

Insomnia (i.e. difficulties with falling or staying asleep) was the primary focus of all CBT interventions except for one study in which nightmares were targeted. Standardised protocols were frequently adapted by omitting sleep restriction on the basis of research linking sleep loss to psychotic experiences.<sup>7,39</sup> Sleep compression (slowly delaying the earliest bedtime) is a standard component of CBT-I and may be a useful alternative to reducing time in bed and increasing sleep efficiency. Other adaptations included strategies to manage delusions and hallucinations that were preventing patients from falling asleep at night-time, problems with oversleeping to escape voices and fears of bed caused by past adverse experiences. Several CBT-I trials also offered to address nightmares, which reflects that insomnia and nightmares can be co-occurring problems for people with psychosis.<sup>25</sup>

Effectiveness on sleep outcomes

The results indicate that CBT is an effective treatment for sleep problems in people with psychosis. All studies observed an improvement on their primary sleep measure, although the quality of studies was highly variable. Out of the four RCT studies that were judged to be at low risk of bias, effect sizes ranged from medium to

very large post-treatment and largely persisted at 3-months’ follow-up. These effects were also all significant except for the smallest RCT, which may have been too underpowered to detect this. The results are congruent with meta-analytic evidence that CBT-I and IRT are effective for healthy adults.<sup>93,94</sup> CBT is the recommended first-line treatment for insomnia and nightmares in clinical guidelines,<sup>18,21</sup> and the findings lend support to its use for people with psychosis.

Effectiveness on psychotic outcomes

Eight studies measured psychotic symptoms such as hallucinations, delusions and paranoid thinking. Study quality ranged from low to critical risk of bias. Out of the four RCTs judged as low risk, effect sizes were small to medium in size and mostly positive. Yet, they were not significant, and some negative effects were obtained (i.e. suggesting either a deterioration in symptoms, or that the treatment group did not improve by as much as the control group). Accordingly, the evidence is inconclusive regarding whether CBT directed at sleep problems leads to improvements in psychotic symptoms.

Of note, in the research literature, a large-scale RCT involving a non-clinical student sample of 3755 participants found that CBT-I led to significant improvements in paranoia and hallucinations.<sup>36</sup> Their mediation analysis supported this interpretation, as improvements in sleep accounted for almost 40–60% of the change in hallucinations and paranoia after treatment. Given that it reported small effect sizes for paranoia and hallucinations, it is possible that the studies included in this review were insufficiently powered to detect significant results (the largest RCT had a sample size of only 50 participants). Alternatively, it is also possible that the link between sleep problems and psychosis is weaker than anticipated. This would have theoretical implications for Freeman’s model<sup>4</sup> in which sleep dysfunction is a putative cause of persecutory delusions.

Effectiveness for other clinical outcomes

In relation to other clinical outcomes, the findings are harder to interpret, partly because of the range of outcomes and measures. The most popular clinical domains were depression, anxiety, mental well-being and quality of life, but each domain was only captured in a small number of studies. Effect sizes were frequently in the direction suggesting an improvement in clinical symptoms, but were mostly non-significant, and thus the evidence is not conclusive.



Many studies in the wider research literature report that poor sleep is linked to depression and anxiety.<sup>95</sup> People who are sleep deprived often describe increased negative emotions such as anger, frustration, sadness and irritability<sup>96,97</sup> and reduced ability to engage in meaningful activities.<sup>98–100</sup> Chronic lack of sleep is also associated with a reduced immune system functioning and other physical health problems.<sup>101</sup> Given these findings, we hypothesised that there would be widespread ripple effects to treating people's sleep problems. A possible explanation for why this was not clearly found is that studies were underpowered to detect effects. Another possibility is that the intervention requires time to improve people's outcomes. If people have experienced years of sleep deprivation and consequently withdrawn from important areas of their life because of fatigue and low mood, it may take time for people to regain their energy, confidence and social networks and re-engage with meaningful activities. Future research should investigate longer-term outcomes.

### Acceptability

The findings of this review indicate that CBT for sleep is acceptable. None of the adverse events that occurred across studies were related to treatment. A meta-analysis has estimated that ~13% of people with schizophrenia drop out from psychosocial treatments,<sup>102</sup> yet the majority of studies included in our review reported lower rates, suggesting that engagement was reasonably good. While drop-out rates ranged from 0 to 27.8%, the highest rates were found in studies with weaker methodological designs where researchers may have struggled to follow-up participants. Of note, no studies consulted participants regarding their reasons for dropping out. This would have been helpful to determine the degree to which drop-out was a valid measure of acceptability or was affected by other changes in participants' circumstances.

The feedback from questionnaires and qualitative interviews provides stronger evidence. All, or nearly all, participants rated treatment acceptable, enjoyable and satisfying. Qualitative themes suggested that they found it useful and experienced widespread improvements in other areas of life. Participants valued an interactive approach in which support was readily accessible and user-friendly. The high levels of commitment required (e.g. in maintaining a consistent sleep window) could be a challenge when implementing strategies long term. A process of trial and error was sometimes required to find out what strategies worked for each participant personally.

### Considerations around implementation

An individualised, biopsychosocial formulation-based approach is important to clarify what factors are maintaining each patient's difficulties.<sup>103</sup> The clinical picture on sleep problems in psychosis is complex and the underlying causes can be varied. Erratic sleep patterns have been documented among patients with psychosis.<sup>104</sup> Often, patients lack daytime activities and are socially isolated. Limited exposure to natural daylight and use of screens at night can result in circadian rhythm disruption where patients go to sleep too early (advanced phase) or too late, (delayed phase), or they oversleep (hypersomnia).<sup>104,105</sup> Lifestyle factors such as napping, poor diet and nicotine can also be disruptive. Some patients experience high levels of night-time worry (including paranoid fears), which can result in insomnia by increasing hyperarousal.<sup>106</sup> It is also important to note that medical sleep disorders may be present, such as sleep apnoea, which shows elevated rates among schizophrenia patients.<sup>107</sup> Hypnagogic and hypnopompic hallucinations can be caused by sleep disorders, particularly narcolepsy, or can be a part of psychosis. Patients' medications may further affect their sleep.<sup>17</sup> For example, there are reports of certain

antidepressants intensifying nightmares.<sup>108</sup> Sedative side-effects of antipsychotic medications can cause daytime fatigue. Hypnotics are commonly prescribed alongside antipsychotics but issues with tolerance and rebound can occur.

Unlike the full range of sleep problems described, the reviewed studies focused on insomnia and nightmares. Indeed, most trials required participants to be stabilised on medication and excluded anyone with a medical sleep disorder. No studies analysed the influence of comorbid sleep disorders and/or medication effects. Clinicians should assess for other sleep disorders and consider the impact of any medications. CBT is unlikely to be indicated or effective for all sleep problems in psychosis, and its appropriateness should be considered in conjunction with existing good clinical practice, including working within a multidisciplinary context and a wider biopsychosocial formulation. We refer to a helpful guide for treating sleep problems in schizophrenia patients<sup>17</sup> that advises linking in with the wider clinical team to establish if a medication review is required and collaborating with relevant organisations (e.g. supported living to implement lifestyle changes). For certain sleep disorders, clinical guidelines advise medical interventions rather than CBT (e.g. continuous positive airway pressure (CPAP) machines for sleep apnoea).<sup>23</sup>

### Strengths and limitations

We provide a pre-registered, rigorous, systematic review of CBT interventions directed at sleep in people with psychosis. Our scope was comprehensive as we considered the full range of psychotic symptoms from at-risk state to full-blown disorders, both quantitative and qualitative methods, a wide range of outcomes and both efficacy and acceptability assessments. A further strength of our study is that a rigorous methodology was used to search for and critically appraise studies, with a second reviewer duplicating several stages of the analysis to ensure interrater reliability. A mixed-methods approach allowed us to triangulate different forms of evidence and strengthen the credibility of our conclusions. We note a recent quantitative-only review with fewer included studies, which was not pre-registered<sup>109</sup> and likely had inflated estimates, because of an inclusion of the same data-set twice<sup>7,110</sup> and an error in the reporting of another paper that we highlighted.<sup>a</sup> The robust, converging and accurate results of our review have clear clinical implications for healthcare professionals seeking to support people with psychosis.

There were nonetheless several limitations in the ability to draw conclusions regarding treatment effectiveness, feasibility and acceptability. There were few high-quality studies. Sample sizes were small, resulting in large confidence intervals that may have meant they were underpowered to detect significant results. The wide variety of measures to assess psychosis and other clinical symptoms made it difficult to generalise. Discharge was a barrier to accessing the full course of treatment in some of the in-patient studies, which made it difficult to compare community versus in-patient treatment. As stated in our pre-registered analysis plan, we intended to conduct a meta-analysis; however, there were too few comparable studies to yield meaningful results. Low numbers of studies also meant we could not identify factors influencing treatment effectiveness including patient-status (full diagnosis versus at-risk mental state), treatment focus (insomnia versus nightmares), specific adaptations, settings, comorbidity and medication effects.

The two qualitative studies included in this review added rich insights into participants' experiences. However, they did not explain the kind of thematic analysis they were performing or its theoretical underpinnings. This is a widespread problem in thematic research.<sup>111</sup> The current review adopted a realist/







essentialist position in seeking to ‘stay close’ to participants’ literal meanings when evaluating treatment acceptability. However, limitations affecting the generalisability of our findings include small numbers of participants and researcher subjectivity influencing the selection of themes. It is unknown whether the results replicate across different settings, modes of treatment, and so on.

Finally, White Western participants tended to be over-represented, and ethnicity was not reported for some studies. This reflects wider problems of underrepresentation of ethnic groups in clinical research.<sup>112</sup> Migrant and ethnic minority status is associated with increased odds of psychotic disorder.<sup>113</sup> It would have been useful to investigate treatment effectiveness and acceptability across cultural contexts.

Future directions

Large-scale RCTs are necessary to establish psychotic and other clinical outcomes. Further investigations of treatment effectiveness and acceptability are also needed for people at risk of psychosis, people from a range of cultural and ethnic backgrounds and CBT for nightmares. It would be helpful to understand reasons for treatment drop-out, and longer-term consequences of treatment (i.e. greater than 3 months’ follow-up). Many clinical practitioners do not routinely ask about patients about their sleep problems.<sup>114</sup> Indeed, clinical guidelines for psychotic disorders, including those by the National Institute of Clinical Excellence,<sup>115</sup> do not focus on sleep. Thus, it would also be useful to investigate how to bridge the research–practice gap<sup>116</sup> and engage practitioners in assessing and offering CBT for sleep problems in this patient group.

In conclusion, this review shows that CBT is highly effective and acceptable in treating sleep problems in people with, or at risk of, psychosis. However, results were inconclusive regarding the wider impact of treatment on patients’ psychotic and other clinical symptoms. Clinicians should be aware that adaptations to standard treatment protocols are commonly made for this population (e.g. omitting sleep restriction) and that certain adjustments may enhance acceptability (e.g. adopting a collaborative approach). High-quality, large-scale RCTs are required to understand the full benefits of treatment and explore what factors influence these.

**Hannah Wilkinson** , Department of Experimental Psychology, Medical Sciences Division, University of Oxford, Oxford, UK; and Oxford Health NHS Foundation Trust, Oxford, UK; **Louise C. Johns** , Department of Experimental Psychology, Medical Sciences Division, University of Oxford, Oxford, UK; and Oxford Health NHS Foundation Trust, Oxford, UK; **Rachel Batchelor** , Department of Experimental Psychology, Medical Sciences Division, University of Oxford, Oxford, UK; and Oxford Health NHS Foundation Trust, Oxford, UK; **Alex Lau-Zhu** , Department of Experimental Psychology, Medical Sciences Division, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Oxford, UK; Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK; and Linacre College, Oxford, UK

**Correspondence:** Hannah Wilkinson. Email: [hannah.wilkinson@psy.ox.ac.uk](mailto:hannah.wilkinson@psy.ox.ac.uk)

First received 13 Aug 2024, final revision 23 Feb 2025, accepted 4 Mar 2025

**Supplementary material**

The supplementary material is available online at <https://doi.org/10.1192/bjp.2025.86>

**Data availability**

The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.

**Author contributions**

H.W. took a lead role in formulating the research questions, analysing the data and writing the article, as part of her clinical doctorate. A.L.-Z. and L.C.J. were supervisors and were involved in formulating research questions and providing guidance and feedback in the write-up of the article. R.B. supported the analyses and write-up of the article.

**Funding**

H.W. and R.B. are funded by Oxford Health National Health Service (NHS) Foundation Trust for doctoral training in clinical psychology. A.L.-Z. also reports funding from a Medical Research Council Clinician Scientist Fellowship (MR/Y009460/1), John Fell Fund from the Oxford University Press (0014097), National Institute of Health Research Imperial Biomedical Research Centre hosted at Imperial College Healthcare NHS Trust (PSP955) and Committee for Children Junior Research Fellowship at Linacre College.

**Declaration of interest**

None.

**Transparency declaration**

The authors affirm that the manuscript is an honest, accurate and transparent account of the study being reported and that no important aspects of the study have been omitted.

**References**

- 1 Reeve S, Sheaves B, Freeman D. Sleep disorders in early psychosis: incidence, severity, and association with clinical symptoms. *Schizophr Bull* 2019; **45**: 287–95.
- 2 Kalmbach DA, Cuamatzi-Castelan AS, Tonnu CV, Tran KM, Anderson JR, Roth T, et al. Hyperarousal and sleep reactivity in insomnia: current insights. *Nat Sci Sleep* 2018; **10**: 193–201.
- 3 Waite F, Sheaves B, Isham L, Reeve S, Freeman D. Sleep and schizophrenia: from epiphenomenon to treatable causal target. *Schizophr Res* 2020; **221**: 44–56.
- 4 Freeman D. Persecutory delusions: a cognitive perspective on understanding and treatment. *Lancet Psychiat* 2016; **3**: 685–92.
- 5 Freeman D, Garety PA, Kuipers E, Fowler D, Bebbington PE. A cognitive model of persecutory delusions. *Br J Clin Psychol* 2002; **41**: 331–47.
- 6 Reeve S, Sheaves B, Freeman D. The role of sleep dysfunction in the occurrence of delusions and hallucinations: a systematic review. *Clin Psychol Rev* 2015; **42**: 96–115.
- 7 Waters F, Chiu V, Atkinson A, Blom JD. Severe sleep deprivation causes hallucinations and a gradual progression toward psychosis with increasing time awake. *Front Psychiatry* 2018; **9**: 303.
- 8 Dudley R, Taylor P, Wickham S. Delusions and the ‘Jumping to conclusions’ reasoning bias: a systematic review and meta-analysis. *Schizophr Bull* 2016; **42**: 652–65.
- 9 Marwaha S, Broome MR, Bebbington PE, Kuipers E, Freeman D. Mood instability and psychosis: analyses of british national survey data. *Schizophr Bull* 2014; **40**: 269–77.
- 10 Westermann S, Lincoln TM. Emotion regulation difficulties are relevant to persecutory ideation. *Psychol Psychother* 2011; **84**: 273–87.
- 11 Sheaves B, Rek S, Freeman D. Nightmares and psychiatric symptoms: a systematic review of longitudinal, experimental, and clinical trial studies. *Clin Psychol Rev* 2023; **100**: 102241.
- 12 Batalla-Martin D, Martorell-Poveda MA, Belzunegui-Eraso A, Miralles Garijo E, Del-Cuerdo Serratos A, Valdearcos Pérez J, et al. The experience of insomnia in patients with schizophrenic disorder: a qualitative study. *Front Psychiatry* 2022; **12**: 805601.
- 13 Ishak WW, Bagot K, Thomas S, Magakian N, Bedwani D, Larson D, et al. Quality of life in patients suffering from insomnia. *Innov Clin Neurosci* 2012; **9**: 13–26.
- 14 Li SX, Lam SP, Zhang J, Yu MWM, Chan JWY, Chan CSY, et al. Sleep disturbances and suicide risk in an 8-year longitudinal study of schizophrenia-spectrum disorders. *Sleep* 2016; **39**: 1275–82.
- 15 Neckelmann D, Mykletun A, Dahl AA. Chronic insomnia as a risk factor for developing anxiety and depression. *Sleep* 2007; **30**: 873–80.
- 16 Waters F, Chiu VW, Janca A, Atkinson A, Ree M. Preferences for different insomnia treatment options in people with schizophrenia and related psychoses: a qualitative study. *Front Psychol* 2015; **6**: 990.
- 17 Waite F, Myers E, Harvey AG, Espie CA, Startup H, Sheaves B, et al. Treating sleep problems in patients with schizophrenia. *Behav Cogn Psychother* 2016; **44**: 273–87.
- 18 National Institute of Clinical Excellence (NICE). *Insomnia: Management*. NICE, 2022 (<https://cks.nice.org.uk/topics/insomnia/management/> [cited 23 May 2023]).
- 19 Borbély AA. A two process model of sleep regulation. *Hum Neurobiol* 1982; **1**: 195–204.
- 20 Walker J, Muench A, Perlis ML, Vargas I. Cognitive behavioral therapy for insomnia (CBT-I): a primer. *Klin Spetsialnaia Psikhologiya Clin Psychol Spec Educ* 2022; **11**: 123–37.

- 21 Aurora RN, Zak RS, Auerbach SH, Casey KR, Chowdhuri S, Karippot A, et al. Best practice guide for the treatment of nightmare disorder in adults. *J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med*. 2010; **6**: 389–401.
- 22 Casement MD, Swanson LM. A meta-analysis of imagery rehearsal for post-trauma nightmares: effects on nightmare frequency, sleep quality, and posttraumatic stress. *Clin Psychol Rev* 2012; **32**: 566–74.
- 23 National Institute of Clinical Excellence (NICE). *Obstructive Sleep Apnoea/Hypopnoea Syndrome and Obesity Hypoventilation Syndrome in Over 16s*. NICE, 2021 (<https://www.nice.org.uk/guidance/ng202> [cited 17 Dec 2024]).
- 24 Freeman D, Waite F, Startup H, Myers E, Lister R, McInerney J, et al. Efficacy of cognitive behavioural therapy for sleep improvement in patients with persistent delusions and hallucinations (BEST): a prospective, assessor-blind, randomised controlled pilot trial. *Lancet Psychiat* 2015; **2**: 975–83.
- 25 Sheaves B, Isham L, Bradley J, Espie C, Barrera A, Waite F, et al. Adapted CBT to stabilize sleep on psychiatric wards: a transdiagnostic treatment approach. *Behav Cogn Psychother* 2018; **46**: 661–75.
- 26 Sheaves B, Holmes EA, Rek S, Taylor KM, Nickless A, Waite F, et al. Cognitive behavioural therapy for nightmares for patients with persecutory delusions (nites): an assessor-blind, pilot randomized controlled trial. *Can J Psychiatry Rev Can Psychiatr* 2019; **64**: 686–96.
- 27 Waite F, Černis E, Kabir T, Iredale E, Johns L, Maughan D, et al. A targeted psychological treatment for sleep problems in young people at ultra-high risk of psychosis in England (SleepWell): a parallel group, single-blind, randomised controlled feasibility trial. *Lancet Psychiat* 2023; **10**: 706–18.
- 28 Hwang DK, Nam M, Lee YJ. The effect of cognitive behavioral therapy for insomnia in schizophrenia patients with sleep disturbance: a non-randomized, assessor-blind trial. *Psychiatry Res* 2019; **274**: 182–8.
- 29 Bradley J, Freeman D, Chadwick E, Harvey AG, Mullins B, Johns L, et al. Treating sleep problems in young people at ultra-high risk of psychosis: a feasibility case series. *Behav Cogn Psychother* 2018; **46**: 276–91.
- 30 Haynes PL, Parthasarathy S, Kersh B, Bootzin RR. Examination of insomnia and insomnia treatment in psychiatric inpatients. *Int J Ment Health Nurs* 2011; **20**: 130–6.
- 31 Holmes EP, Corrigan PW, Knight S, Flaxman J. Development of a sleep management program for people with severe mental illness. *Psychiatr Rehabil J* 1995; **19**: 9–15.
- 32 Myers E, Startup H, Freeman D. Cognitive behavioural treatment of insomnia in individuals with persistent persecutory delusions: a pilot trial. *J Behav Ther Exp Psychiatry* 2011; **42**: 330–6.
- 33 Novak C, Packer E, Paterson A, Rosh A, Locke R, Keown P, et al. Feasibility and utility of enhanced sleep management on in-patient psychiatry wards. *BJPsych Bull* 2020; **44**: 255–60.
- 34 Waters F, Chiu VW, Dragovic M, Ree M. Different patterns of treatment response to Cognitive-Behavioural Therapy for Insomnia (CBT-I) in psychosis. *Schizophr Res* 2020; **221**: 57–62.
- 35 Taylor KM, Bradley J, Cella M. A novel smartphone-based intervention targeting sleep difficulties in individuals experiencing psychosis: a feasibility and acceptability evaluation. *Psychol Psychother Theory Res Pract* 2022; **95**: 717–37.
- 36 Freeman D, Sheaves B, Goodwin GM, Yu LM, Nickless A, Harrison PJ, et al. The effects of improving sleep on mental health (OASIS): a randomised controlled trial with mediation analysis. *Lancet Psychiat* 2017; **4**: 749–58.
- 37 Batalla-Martin D, Martorell-Poveda M.-A, Belzunegui-Eraso A, Marieges Gordo A, Batlle Lleal H, Pasqual Melendez R, et al. A pilot nurse-administered CBT intervention for insomnia in patients with schizophrenic disorder: a randomized clinical effectiveness trial. *J Clin Med* 2023; **12**: 6147.
- 38 Kyle SD, Miller CB, Rogers Z, Siriwardena AN, MacMahon KM, Espie CA. Sleep restriction therapy for insomnia is associated with reduced objective total sleep time, increased daytime somnolence, and objectively impaired vigilance: implications for the clinical management of insomnia disorder. *Sleep* 2014; **37**: 229–37.
- 39 Reeve S, Emsley R, Sheaves B, Freeman D. Disrupting sleep: the effects of sleep loss on psychotic experiences tested in an experimental study with mediation analysis. *Schizophr Bull*. 2018; **44**: 662–71.
- 40 Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009; **339**: b2535.
- 41 Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. *BMJ* 2021; **372**: n160.
- 42 Cohen J. A coefficient of agreement for nominal scales. *Educ Psychol Meas* 1960; **20**: 37–46.
- 43 Cohen J. *Statistical Power Analysis for the Behavioral Sciences* 2nd ed. Routledge, 1988.
- 44 Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. *BMC Health Serv Res* 2017; **17**: 88.
- 45 Lewis C, Roberts NP, Gibson S, Bisson JI. Dropout from psychological therapies for post-traumatic stress disorder (PTSD) in adults: systematic review and meta-analysis. *Eur J Psychotraumatology* 2020; **11**: 1709709.
- 46 Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019; **366**: l4898.
- 47 Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016; **355**: i4919.
- 48 Braun V, Clarke V. One size fits all? What counts as quality practice in (reflexive) thematic analysis? *Qual Res Psychol* 2021; **18**: 328–52.
- 49 Couto E, Pike E, Torkilsen EB, Klemp M. Inter-rater reliability of the Risk Of Bias Assessment Tool: for Non-Randomized Studies of Interventions (ACROBAT-NRSI). Cochrane, 2015 (<https://abstracts.cochrane.org/2015-vie-nna/inter-rater-reliability-risk-bias-assessment-tool-non-randomized-studies-interventions>).
- 50 Jerayaman M, Rabbani R, Robson R, Copstein L, Al-Yousif N, Xia J, et al. Inter-rater reliability, inter-consensus reliability and evaluator burden of ROBINS-E and ROBINS-I: a cross-sectional study. Cochrane, 2019 (<https://abstracts.cochrane.org/2019-santiago/inter-rater-reliability-inter-consensus-reliability-and-evaluator-burden-robins-e-and> [cited 30 Apr 2024]).
- 51 Minozzi S, Cinquini M, Gianola S, Gonzalez-Lorenzo M, Banzi R. The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application. *J Clin Epidemiol* 2020; **126**: 37–44.
- 52 Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ* 2017; **358**: j4008.
- 53 Waite F, Bradley J, Chadwick E, Reeve S, Bird JC, Freeman D. The experience of sleep problems and their treatment in young people at ultra-high risk of psychosis: a thematic analysis. *Front Psychiatry* 2018; **9**: 375.
- 54 Edinger JD, Carney CE, Edinger JD, Carney CE. *Overcoming Insomnia: A Cognitive-Behavioral Therapy Approach, Workbook* 2nd ed. Oxford University Press, 2014.
- 55 Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. *Sleep Med* 2001; **2**: 297–307.
- 56 Krakow B. Nightmare complaints in treatment-seeking patients in clinical sleep medicine settings: diagnostic and treatment implications. *Sleep* 2006; **29**: 1313–9.
- 57 Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res* 1989; **28**: 193–213.
- 58 Hauri P, Linde S. *No More Sleepless Nights*: 308. Wiley, 1990.
- 59 Bell V, Halligan PW, Ellis HD. The Cardiff Anomalous Perceptions Scale (CAPS): a new validated measure of anomalous perceptual experience. *Schizophr Bull* 2006; **32**: 366–77.
- 60 Černis E, Beierl E, Molodyski A, Ehlers A, Freeman D. A new perspective and assessment measure for common dissociative experiences: 'Felt Sense of Anomaly'. *PLoS One* 2021; **16**: e0247037.
- 61 Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell'Olio M, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. *Aust N Z J Psychiatry* 2005; **39**: 964–71.
- 62 Green CEL, Freeman D, Kuipers E, Bebbington P, Fowler D, Dunn G, et al. Measuring ideas of persecution and social reference: the Green et al. Paranoid Thought Scales (GPTS). *Psychol Med* 2008; **38**: 101–11.
- 63 Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry* 1998; **59**(Suppl 20): 22–33.
- 64 Kay SR. *Positive and Negative Syndromes in Schizophrenia: Assessment and Research*: 306. Psychology Press, 1991.
- 65 Haddock G, McCarron J, Tarrier N, Faragher EB. Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS). *Psychol Med* 1999; **29**: 879–89.
- 66 Freeman D, Loe BS, Kingdon D, Startup H, Molodyski A, Rosebrock L, et al. The revised Green et al., Paranoid Thoughts Scale (R-GPTS): psychometric properties, severity ranges, and clinical cut-offs. *Psychol Med* 2021; **51**: 244–53.
- 67 Ronald A, Sieradzka D, Cardno AG, Haworth CMA, McGuire P, Freeman D. Characterization of psychotic experiences in adolescence using the specific psychotic experiences questionnaire: findings from a study of 5000 16-year-old twins. *Schizophr Bull* 2014; **40**: 868–77.
- 68 Reiss S, Peterson RA, Gursky DM, McNally RJ. Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. *Behav Res Ther* 1986; **24**: 1–8.
- 69 Steinberg L, Sharp C, Stanford MS, Sharp AT. New tricks for an old measure: the development of the Barratt Impulsiveness Scale-Brief (BIS-Brief). *Psychol Assess* 2013; **25**(1): 216–26.

- 70 Fowler D, Freeman D, Smith B, Kuipers E, Bebbington P, Bashforth H, et al. The Brief Core Schema Scales (BCSS): psychometric properties and associations with paranoia and grandiosity in non-clinical and psychosis samples. *Psychol Med* 2006; **36**: 749–59.
- 71 Beck AT, Steer RA, Brown GK. *BDI-II Manual*. The Psychological Corporation, 1996.
- 72 Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. *J Consult Clin Psychol* 1979; **47**: 343–52.
- 73 Greenwood KE, Sweeney A, Williams S, Garety P, Kuipers E, Scott J, et al. CHOICE of Outcome In CBT for psychoses (CHOICE): the development of a new service user-led outcome measure of CBT for psychosis. *Schizophr Bull* 2010; **36**: 126–35.
- 74 Connell J, Barkham M. *CORE-10 User Manual, Version 1.1*. CORE System Trust & CORE Information Management Systems Ltd, 2007.
- 75 Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. *Am J Psychiatry* 2011; **168**: 1266–77.
- 76 Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. *Behav Res Ther* 1995; **33**: 335–43.
- 77 Dalen C, Carlson E. *Severity of Dissociative Symptoms – Adult (Brief Dissociative Experiences Scale [DES-B] – Modified)*. APA, 2010 (<https://psycnet.apa.org.ezproxy-prd.bodleian.ox.ac.uk/record/1997-04647-022> [cited 23 Mar 2024]).
- 78 Freeman D, Bird JC, Loe BS, Kingdon D, Startup H, Clark DM, et al. The Dunn Worry Questionnaire and the Paranoia Worries Questionnaire: new assessments of worry. *Psychol Med* 2020; **50**: 771–80.
- 79 Brooks R, Rabin R, de Charro F. *The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective*. Kluwer Academic Publishers, 2003.
- 80 Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res Int J Qual Life Asp Treat Care Rehabil* 2011; **20**: 1727–36.
- 81 Priebe S, Huxley P, Knight S, Evans S. *Manchester Short Assessment of Quality of Life (MANSA) [database record]*. APA PsycTests, 1999 (<https://doi.org/10.1037/t10432-000>).
- 82 Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. *J Psychosom Res* 1995; **39**: 315–25.
- 83 Lambe S, Bird JC, Loe BS, Rosebrock L, Kabir T, Petit A, et al. The Oxford agoraphobic avoidance scale. *Psychol Med* 2023; **53**: 1233–43.
- 84 Kroenke K, Spitzer RL, Williams JBW, Löwe B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. *Psychosomatics* 2009; **50**: 613–21.
- 85 Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. *Psychosom Med* 2002; **64**: 258–66.
- 86 Law H, Neil ST, Dunn G, Morrison AP. Psychometric properties of the questionnaire about the process of recovery (QPR). *Schizophr Res* 2014; **156**: 184–9.
- 87 Keetharuth AD, Brazier J, Connell J, Bjorner JB, Carlton J, Taylor Buck E, et al. Recovering Quality of Life (ReQoL): a new generic self-reported outcome measure for use with people experiencing mental health difficulties. *Br J Psychiatry* 2018; **212**: 42–9.
- 88 Tennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, et al. The Warwick-Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation. *Health Qual Life Outcomes* 2007; **5**: 63.
- 89 Mundt JC, Marks IM, Shear MK, Greist JH. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. *Br J Psychiatry J Ment Sci* 2002; **180**: 461–4.
- 90 Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. *Br J Psychiatry J Ment Sci* 1978; **133**: 429–35.
- 91 Tarnowski KJ, Simonian SJ. Assessing treatment acceptance: the abbreviated acceptability rating profile. *J Behav Ther Exp Psychiatry* 1992; **23**: 101–6.
- 92 Edwards CJ, Cella M, Tarrier N, Wykes T. The optimisation of experience sampling protocols in people with schizophrenia. *Psychiatry Res* 2016; **244**: 289–93.
- 93 van Straten A, van der Zweerde T, Kleiboer A, Cuijpers P, Morin CM, Lancee J. Cognitive and behavioral therapies in the treatment of insomnia: a meta-analysis. *Sleep Med Rev* 2018; **38**: 3–16.
- 94 Yücel DE, van Emmerik AAP, Souama C, Lancee J. Comparative efficacy of imagery rehearsal therapy and prazosin in the treatment of trauma-related nightmares in adults: a meta-analysis of randomized controlled trials. *Sleep Med Rev* 2020; **50**: 101248.
- 95 Hertenstein E, Trinca E, Wunderlin M, Schneider CL, Zust MA, Feher KD, et al. Cognitive behavioral therapy for insomnia in patients with mental disorders and comorbid insomnia: a systematic review and meta-analysis. *Sleep Med Rev* 2022; **62**: 101597.
- 96 Killgore WDS, Weber M. Sleep deprivation and cognitive performance. In *Sleep Deprivation and Disease: Effects on the Body, Brain and Behavior* (eds WDS Killgore, M Weber): 209–29. Springer, 2014.
- 97 Tomaso CC, Johnson AB, Nelson TD. The effect of sleep deprivation and restriction on mood, emotion, and emotion regulation: three meta-analyses in one. *Sleep* 2020; **44**: zsa289.
- 98 Ben Simon E, Walker MP. Sleep loss causes social withdrawal and loneliness. *Nat Commun* 2018; **9**: 3146.
- 99 Friedman JH. Sleep disturbances in Parkinson's disease: beyond a regional perspective. Time to do something about it. *Int Psychogeriatr* 2020; **32**: 793–4.
- 100 Wade AG. The societal costs of insomnia. *Neuropsychiatr Dis Treat* 2010; **7**: 1–18.
- 101 Colten HR, Altevogt BM, Institute of Medicine (US) Committee on Sleep Medicine and Research, eds. Extent and health consequences of chronic sleep loss and sleep disorders. In *Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem*. National Academies Press, 2006 (<https://www.ncbi.nlm.nih.gov/books/NBK19961/> [cited 30 Apr 2024]).
- 102 Villeneuve K, Potvin S, Lesage A, Nicole L. Meta-analysis of rates of drop-out from psychosocial treatment among persons with schizophrenia spectrum disorder. *Schizophr Res* 2010; **121**: 266–70.
- 103 Persons JB, Brown CL, Diamond A. Case formulation-driven cognitive-behavioral therapy. In *Handbook of Cognitive-Behavioral Therapies*, 4th ed (eds KS Dobson, DJA Dozois): 145–68. Guilford Press, 2019.
- 104 Wulff K, Dijk DJ, Middleton B, Foster RG, Joyce EM. Sleep and circadian rhythm disruption in schizophrenia. *Br J Psychiatry J Ment Sci* 2012; **200**: 308–16.
- 105 Strassnig MT, Harvey PD, Miller ML, Depp CA, Granholm E. Real world sedentary behavior and activity levels in patients with schizophrenia and controls: an ecological momentary assessment study. *Ment Health Phys Act* 2021; **20**: 100364.
- 106 Riemann D, Spiegelhalter K, Feige B, Voderholzer U, Berger M, Perlis M, et al. The hyperarousal model of insomnia: a review of the concept and its evidence. *Sleep Med Rev* 2010; **14**: 19–31.
- 107 Myles H, Myles N, Antic NA, Adams R, Chandratilleke M, Liu D, et al. Obstructive sleep apnea and schizophrenia: a systematic review to inform clinical practice. *Schizophr Res* 2016; **170**: 222–5.
- 108 Tribl GG, Wetter TC, Schredl M. Dreaming under antidepressants: a systematic review on evidence in depressive patients and healthy volunteers. *Sleep Med Rev* 2013; **17**: 133–42.
- 109 Ugurlu M, Ugurlu GK, Sahin EK, Kamis GZ, Caykoylu A. Short and long-term effects of cognitive behavioral therapy on sleep problems and psychotic symptoms in patients with psychotic disorders: a meta-analysis study. *Braz J Psychiatry* 2025; **47**: e20243623.
- 110 Chiu, VW, Ree M, Janca A, Iyyalol R, Dragovic M, Waters F. Sleep profiles and CBT-I response in schizophrenia and related psychoses. *Psychiatry Res* 2018; **268**: 279–87.
- 111 Braun V, Clarke V. Toward good practice in thematic analysis: avoiding common problems and becoming a knowing researcher. *Int J Transgender Health*. 2023; **24**: 1–6.
- 112 Redwood S, Gill PS. Under-representation of minority ethnic groups in research – call for action. *Br J Gen Pract* 2013; **63**: 342–3.
- 113 Termorshuizen F, van der Ven E, Tarricone I, Jongsma HE, Gayer-Anderson C, Lasalvia A, et al. The incidence of psychotic disorders among migrants and minority ethnic groups in Europe: findings from the multinational EU-GEI study. *Psychol Med* 2022; **52**: 1376–85.
- 114 Rehman A, Waite F, Sheaves B, Biello S, Freeman D, Gumley A. Clinician perceptions of sleep problems and their treatment in patients with non-affective psychosis. *J Sleep Res*. 2016; **25**(Supplement 1): 283.
- 115 National Institute of Clinical Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. NICE, 2014 (<https://www.nice.org.uk/guidance/cg178> [cited 17 Jan 2025]).
- 116 Robinson A, Moghaddam N. Psychological treatments and therapy adaptations for psychological distress in dementia and mild cognitive impairment: a systematic review and meta-analysis. *Ment Health Rev J* 2022; **27**: 295–318.
- 117 *Manchester Short Assessment of Quality of Life (MANSA)*. APA, 1999.